Educational draft · awaiting clinical reviewThe full textbook explains uncertainty but does not replace live national or local guidance, specialist advice, or current prescribing information.
Use clozapine blood monitoring correctly, recognise myocarditis and infection warnings promptly, and prevent serious harm from treatment breaks, intestinal hypomotility, interactions and fragmented prescribing responsibility.
Clozapine is used for treatment-resistant schizophrenia after adequate trials of other antipsychotics, and in specified Parkinson's disease psychosis settings. Its benefit can be substantial, making reliable safety systems especially important. A blood-monitoring service controls supply because clozapine can suppress neutrophils. However, haematological clearance is only one element of safe treatment: a green result does not exclude myocarditis, toxicity, bowel obstruction, hyperglycaemia or orthostatic collapse.
The white cell count and absolute neutrophil count answer a different question from a plasma clozapine level. The former identifies impaired infection defence; the latter helps assess drug exposure in relation to dose, adherence, smoking, infection and interactions. Both can be required in an acutely unwell patient. Document which test is being requested and why, because an ambiguous instruction to check a clozapine blood test can lead to the wrong investigation.
Cardiac symptoms deserve particular vigilance during titration. Tachycardia can occur without myocarditis, but persistent resting tachycardia with fever, chest pain, breathlessness or unexplained fatigue cannot simply be attributed to an expected adverse effect. Myocarditis risk is greatest during the first two months but is not confined to them. The diagnostic assessment uses symptoms, observations, ECG, biomarkers and cardiac imaging; no single normal early result proves the diagnosis is excluded.
Fever, sore throat, oral ulceration or flu-like illness may be the first clue to a dangerous fall in neutrophils.
Persistent resting tachycardia with dyspnoea, chest discomfort, tachypnoea or unusual fatigue is more concerning than an isolated pulse increase.
New marked sedation, confusion, slurred speech, myoclonus, seizures or worsened salivation can follow infection, smoking cessation or an interacting medicine.
Ask when stool was last passed and about pain, distension and vomiting; diarrhoea can represent overflow around faecal impaction.
At age 60 or over start with 12.5 mg once on day one. Retitration depends on prior tolerance, illness and interactions; never restart the previous full dose after a qualifying break or bypass monitoring-service clearance.
People with confirmed Duffy-null associated neutrophil counts may have a formally approved alternative monitoring pathway; do not infer eligibility from appearance or ancestry alone.
It can indicate neutropenia and simultaneously reduce clozapine metabolism, so infection assessment and exposure assessment may both be necessary.
A transient fever can occur early, but infection, agranulocytosis, myocarditis and neuroleptic malignant syndrome require consideration before reassurance.
Abrupt clozapine cessation can cause cholinergic rebound and rapid psychotic deterioration, so emergency cessation must be accompanied by coordinated psychiatric management.
Calling a clozapine concentration a normal blood result and assuming this permits supply without checking the monitoring service.
Waiting for the next routine count when a patient reports fever and sore throat.
Treating overflow diarrhoea with an antimotility medicine before examining for impaction or obstruction.
Restarting a long-standing maintenance dose after a three-day medical admission without confirming actual administration.
Using European or US monitoring changes to alter a UK brand-specific schedule without an applicable UK authorisation.
Your practice draft is saved in this browser.
A patient with a normal clozapine monitoring result four days ago develops fever, sore throat and mouth ulcers. They are haemodynamically stable. Which investigation is required immediately?
National guidance is shown before implementation-dependent detail. Typical adult dose examples remain subject to patient factors, contraindications and the live BNF or specialist protocol. Source check completed 7 Sept 2026; clinical approval remains outstanding.
Editorial contact: Doctor’s Passport editorial team. Source-check date is separate from clinical approval. Report a content problem · Content changes
Safe continuity depends on knowing the last administered dose, not just the prescription. Acute admission, vomiting, swallowing problems, supply failure or a missed monitoring appointment may interrupt exposure. Restarting the old dose after loss of tolerance can cause profound hypotension, collapse or respiratory compromise. Liaise early with the clozapine team and pharmacist, reconcile the brand and dose, and distinguish a dose-retitration requirement from a separate change in blood-monitoring frequency.